CELC
Celcuity Inc.
$93.02
-2.68
(-2.80%)
Mkt Cap
4.54B
Volume
940,412
52W Range
44.42-151.02
Sector
Healthcare
Beta
0.16
EPS (TTM)
-4.29 USD
P/E Ratio
-26.39
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (177.04M) | (111.78M) | (63.78M) | (40.37M) | (29.61M) | (9.47M) | (7.36M) | (7.48M) | (6.25M) | (3.31M) | (2.26M) |
| EPS | -3.78 | -2.83 | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Free Cash Flow | (153.53M) | (83.72M) | (53.91M) | (36.17M) | (20.39M) | (7.24M) | (6.38M) | (6.71M) | (5.19M) | (2.93M) | (2.06M) |
| FCF / Share | -2.92 | -2.12 | -2.28 | -2.35 | -1.52 | -0.70 | -0.62 | -0.66 | -0.70 | -0.44 | -0.33 |
| Operating CF | (153.28M) | (83.47M) | (53.81M) | (36.01M) | (20.31M) | (7.15M) | (6.00M) | (6.08M) | (4.95M) | (2.89M) | (1.98M) |
| Total Assets | 466.56M | 245.12M | 191.22M | 175.70M | 85.91M | 12.96M | 20.28M | 26.03M | 31.97M | 6.06M | 5.30M |
| Total Debt | 195.38M | 97.95M | 37.45M | 35.24M | 14.89M | 262,488 | 256,137 | 25,608 | 0 | 0 | 0 |
| Cash & Equiv | 165.70M | 22.51M | 30.66M | 24.57M | 84.29M | 11.64M | 18.74M | 15.94M | 2.64M | 5.86M | 5.07M |
| Book Value | 100.56M | 115.62M | 139.77M | 133.77M | 68.71M | 11.70M | 19.30M | 25.35M | 31.39M | 5.61M | 5.02M |
| Return on Equity | -1.76 | -0.97 | -0.46 | -0.30 | -0.43 | -0.81 | -0.38 | -0.30 | -0.20 | -0.59 | -0.45 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.86M) | (52.84M) | (50.97M) | (43.80M) | (45.27M) | (37.00M) | (36.65M) | (29.79M) | (23.72M) | (21.61M) | (18.85M) | (18.40M) |
| EPS | -1.44 | -0.97 | -0.96 | -0.92 | -1.04 | -0.86 | -0.85 | -0.70 | -0.62 | -0.64 | -0.65 | -0.83 |
| Free Cash Flow | (55.48M) | (55.31M) | (36.45M) | (44.91M) | (36.25M) | (35.91M) | (27.82M) | (20.61M) | (18.13M) | (17.16M) | (18.57M) | (12.80M) |
| FCF / Share | -1.01 | -1.02 | -0.69 | -1.00 | -0.83 | -0.83 | -0.65 | -0.48 | -0.47 | -0.51 | -0.64 | -0.58 |
| Operating CF | (55.43M) | (55.06M) | (36.40M) | (44.82M) | (36.21M) | (35.85M) | (27.77M) | (20.56M) | (18.07M) | (17.07M) | (18.54M) | (12.75M) |
| Total Assets | 828.22M | 410.16M | 466.56M | 476.00M | 183.59M | 218.13M | 245.12M | 273.04M | 292.54M | 188.18M | 191.22M | 142.38M |
| Total Debt | 754.38M | 195.58M | 195.38M | 320.35M | 99.42M | 98.71M | 97.95M | 97.19M | 96.51M | 37.93M | 37.45M | 36.97M |
| Cash & Equiv | 182.05M | 145.19M | 165.70M | 74.25M | 46.35M | 16.48M | 22.51M | 12.60M | 30.46M | 31.21M | 30.66M | 25.76M |
| Book Value | (12.78M) | 53.52M | 100.56M | 116.96M | 44.38M | 86.67M | 115.62M | 149.71M | 176.68M | 133.74M | 139.77M | 92.90M |
| Return on Equity | N/A | -0.99 | -0.51 | -0.37 | -1.02 | -0.43 | -0.32 | -0.20 | -0.13 | -0.16 | -0.13 | -0.20 |
CELC News
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Q2 Earnings Call Highlights
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC